Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy

Description

A Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy

Conditions

Prostate Cancer

Study Overview

Study Details

Study overview

A Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy

A Phase 1 Dose Escalation Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy

Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy

Condition
Prostate Cancer
Intervention / Treatment

-

Contacts and Locations

Tucson

Arizona Urology Specialists, Tucson, Arizona, United States, 85715

Gainesville

University of Florida, Gainesville, Florida, United States, 32608

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Males aged 18 years or older at time of informed consent.
  • 2. Have a histologically confirmed diagnosis of prostate cancer, and are scheduled to undergo radical prostatectomy within 28 days of screening.
  • 3. Grade Group 2-5.
  • 4. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤2 at Screening.
  • 5. Have adequate organ and bone marrow function at screening.
  • 6. Able to understand and be willing to sign an Institutional Review Board/Ethics Committee-approved written informed consent document
  • 1. Have an invasive malignancy, other than the disease under study.
  • 2. Anticipated to require the use of a drain after radical prostatectomy.
  • 3. Received any other anticancer therapy (e.g., including but not limited to chemotherapy, biologic therapy, immunotherapy, targeted therapy, endocrine therapy, radiation therapy, intravesical therapy ) within 28 days.
  • 4. History of allergic reactions attributed to compounds of similar chemical or biologic composition as those used in the STM-416p formulation including poloxamer 407 and sodium hyaluronate.
  • 5. History of allogeneic organ transplant.
  • 6. History of primary immunodeficiency.
  • 7. QTc interval \>470 msec at Screening.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

MALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

SURGE Therapeutics,

Study Record Dates

2026-03